APO RESEARCH · REPORT
Nausea And Vomiting Treatment
Nausea and Vomiting Treatment also called Antiemetics. Antiemetics included aprepitant, diphenhydramine, granisetron, hydroxyzine, meclizine, ondansetron, prochlorperazine, promethazine, scopolamine, metoclopramide, trimethobenzamide, palonosetron, dolasetron, and thiethylperazine, etc.
Product & engineering
Understand the product.
Nausea and Vomiting Treatment also called Antiemetics. Antiemetics included aprepitant, diphenhydramine, granisetron, hydroxyzine, meclizine, ondansetron, prochlorperazine, promethazine, scopolamine, metoclopramide, trimethobenzamide, palonosetron, dolasetron, and thiethylperazine, etc.
Selected research
Industry Research
Nausea And Vomiting Treatment Industry Research Report 2026
Market perspective
Nausea and Vomiting Treatment also called Antiemetics. Antiemetics included aprepitant, diphenhydramine, granisetron, hydroxyzine, meclizine, ondansetron, prochlorperazine, promethazine, scopolamine, metoclopramide, trimethobenzamide, palonosetron, dolasetron, and thiethylperazine, etc.
United States is the largest Nausea And Vomiting Treatment market with about 42% market share. Europe is follower, accounting for about 20% market share.Merck & Co. Inc. was the global greatest company in Nausea And Vomiting Treatment industry, with the market Share of 14% , followed by Helsinn Group, Unimed Pharmaceuticals (AbbVie Inc.), Kyowa Kirin, Sanofi, Qilu Pharma, Teva Pharmaceutical Industries Ltd., Taiji group, Novartis, Heron Therapeutics, Atnahs Pharma UK Limited, Mylan, Duchesnay, Tesaro.
Report Scope
Read the full market overview
This report quantifies the global Nausea And Vomiting Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nausea And Vomiting Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nausea And Vomiting Treatment Market by Company
Merck & Co. Inc.
Helsinn Group
Unimed Pharmaceuticals (AbbVie Inc.)
Kyowa Kirin
Sanofi
Qilu Pharma
Teva Pharmaceutical Industries Ltd.
Taiji group
Novartis
Heron Therapeutics
Atnahs Pharma UK Limited
Mylan
Duchesnay
Tesaro
Nausea And Vomiting Treatment Segment by Type
Serotonin Receptor Antagonist
Neurokinin NK1 Receptor Antagonist
Others
Nausea And Vomiting Treatment Segment by Application
CINV
PONV
Motion Sickness
Pregnancy
Others
Nausea And Vomiting Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nausea And Vomiting Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nausea And Vomiting Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nausea And Vomiting Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nausea And Vomiting Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Serotonin Receptor Antagonist
- Neurokinin NK1 Receptor Antagonist
- Others
Applications
- CINV
- PONV
- Motion Sickness
- Pregnancy
- Others
Companies covered
- Merck & Co. Inc.
- Helsinn Group
- Unimed Pharmaceuticals (AbbVie Inc.)
- Kyowa Kirin
- Sanofi
- Qilu Pharma
- Teva Pharmaceutical Industries Ltd.
- Taiji group
- Novartis
- Heron Therapeutics
- Atnahs Pharma UK Limited
- Mylan
- Duchesnay
- Tesaro
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nausea And Vomiting Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Serotonin Receptor Antagonist
- 2.2.3 Neurokinin NK1 Receptor Antagonist
- 2.2.4 Others
- 2.3 Nausea And Vomiting Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 CINV
- 2.3.3 PONV
- 2.3.4 Motion Sickness
- 2.3.5 Pregnancy
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Nausea And Vomiting Treatment Breakdown Data by Type
- 3.1 Global Nausea And Vomiting Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Nausea And Vomiting Treatment Forecasted Market Size by Type (2027-2032)
4 Nausea And Vomiting Treatment Breakdown Data by Application
- 4.1 Global Nausea And Vomiting Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Nausea And Vomiting Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nausea And Vomiting Treatment Market Perspective (2021-2032)
- 5.2 Global Nausea And Vomiting Treatment Growth Trends by Region
- 5.2.1 Global Nausea And Vomiting Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nausea And Vomiting Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Nausea And Vomiting Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Nausea And Vomiting Treatment Market Dynamics
- 5.3.1 Nausea And Vomiting Treatment Industry Trends
- 5.3.2 Nausea And Vomiting Treatment Market Drivers
- 5.3.3 Nausea And Vomiting Treatment Market Challenges
- 5.3.4 Nausea And Vomiting Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nausea And Vomiting Treatment Players by Revenue
- 6.1.1 Global Top Nausea And Vomiting Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Nausea And Vomiting Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Nausea And Vomiting Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nausea And Vomiting Treatment Head Office and Area Served
- 6.4 Global Nausea And Vomiting Treatment Players, Product Type & Application
- 6.5 Global Nausea And Vomiting Treatment Manufacturers Established Date
- 6.6 Global Nausea And Vomiting Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nausea And Vomiting Treatment Market Size (2021-2032)
- 7.2 North America Nausea And Vomiting Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nausea And Vomiting Treatment Market Size by Country (2021-2026)
- 7.4 North America Nausea And Vomiting Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nausea And Vomiting Treatment Market Size (2021-2032)
- 8.2 Europe Nausea And Vomiting Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nausea And Vomiting Treatment Market Size by Country (2021-2026)
- 8.4 Europe Nausea And Vomiting Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nausea And Vomiting Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Nausea And Vomiting Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nausea And Vomiting Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nausea And Vomiting Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nausea And Vomiting Treatment Market Size (2021-2032)
- 10.2 South America Nausea And Vomiting Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nausea And Vomiting Treatment Market Size by Country (2021-2026)
- 10.4 South America Nausea And Vomiting Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nausea And Vomiting Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Nausea And Vomiting Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nausea And Vomiting Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nausea And Vomiting Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck & Co. Inc.
- 12.1.1 Merck & Co. Inc. Company Information
- 12.1.2 Merck & Co. Inc. Business Overview
- 12.1.3 Merck & Co. Inc. Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.1.4 Merck & Co. Inc. Nausea And Vomiting Treatment Product Portfolio
- 12.1.5 Merck & Co. Inc. Recent Developments
- 12.2 Helsinn Group
- 12.2.1 Helsinn Group Company Information
- 12.2.2 Helsinn Group Business Overview
- 12.2.3 Helsinn Group Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.2.4 Helsinn Group Nausea And Vomiting Treatment Product Portfolio
- 12.2.5 Helsinn Group Recent Developments
- 12.3 Unimed Pharmaceuticals (AbbVie Inc.)
- 12.3.1 Unimed Pharmaceuticals (AbbVie Inc.) Company Information
- 12.3.2 Unimed Pharmaceuticals (AbbVie Inc.) Business Overview
- 12.3.3 Unimed Pharmaceuticals (AbbVie Inc.) Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.3.4 Unimed Pharmaceuticals (AbbVie Inc.) Nausea And Vomiting Treatment Product Portfolio
- 12.3.5 Unimed Pharmaceuticals (AbbVie Inc.) Recent Developments
- 12.4 Kyowa Kirin
- 12.4.1 Kyowa Kirin Company Information
- 12.4.2 Kyowa Kirin Business Overview
- 12.4.3 Kyowa Kirin Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.4.4 Kyowa Kirin Nausea And Vomiting Treatment Product Portfolio
- 12.4.5 Kyowa Kirin Recent Developments
- 12.5 Sanofi
- 12.5.1 Sanofi Company Information
- 12.5.2 Sanofi Business Overview
- 12.5.3 Sanofi Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.5.4 Sanofi Nausea And Vomiting Treatment Product Portfolio
- 12.5.5 Sanofi Recent Developments
- 12.6 Qilu Pharma
- 12.6.1 Qilu Pharma Company Information
- 12.6.2 Qilu Pharma Business Overview
- 12.6.3 Qilu Pharma Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.6.4 Qilu Pharma Nausea And Vomiting Treatment Product Portfolio
- 12.6.5 Qilu Pharma Recent Developments
- 12.7 Teva Pharmaceutical Industries Ltd.
- 12.7.1 Teva Pharmaceutical Industries Ltd. Company Information
- 12.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 12.7.3 Teva Pharmaceutical Industries Ltd. Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.7.4 Teva Pharmaceutical Industries Ltd. Nausea And Vomiting Treatment Product Portfolio
- 12.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments
- 12.8 Taiji group
- 12.8.1 Taiji group Company Information
- 12.8.2 Taiji group Business Overview
- 12.8.3 Taiji group Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.8.4 Taiji group Nausea And Vomiting Treatment Product Portfolio
- 12.8.5 Taiji group Recent Developments
- 12.9 Novartis
- 12.9.1 Novartis Company Information
- 12.9.2 Novartis Business Overview
- 12.9.3 Novartis Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.9.4 Novartis Nausea And Vomiting Treatment Product Portfolio
- 12.9.5 Novartis Recent Developments
- 12.10 Heron Therapeutics
- 12.10.1 Heron Therapeutics Company Information
- 12.10.2 Heron Therapeutics Business Overview
- 12.10.3 Heron Therapeutics Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.10.4 Heron Therapeutics Nausea And Vomiting Treatment Product Portfolio
- 12.10.5 Heron Therapeutics Recent Developments
- 12.11 Atnahs Pharma UK Limited
- 12.11.1 Atnahs Pharma UK Limited Company Information
- 12.11.2 Atnahs Pharma UK Limited Business Overview
- 12.11.3 Atnahs Pharma UK Limited Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.11.4 Atnahs Pharma UK Limited Nausea And Vomiting Treatment Product Portfolio
- 12.11.5 Atnahs Pharma UK Limited Recent Developments
- 12.12 Mylan
- 12.12.1 Mylan Company Information
- 12.12.2 Mylan Business Overview
- 12.12.3 Mylan Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.12.4 Mylan Nausea And Vomiting Treatment Product Portfolio
- 12.12.5 Mylan Recent Developments
- 12.13 Duchesnay
- 12.13.1 Duchesnay Company Information
- 12.13.2 Duchesnay Business Overview
- 12.13.3 Duchesnay Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.13.4 Duchesnay Nausea And Vomiting Treatment Product Portfolio
- 12.13.5 Duchesnay Recent Developments
- 12.14 Tesaro
- 12.14.1 Tesaro Company Information
- 12.14.2 Tesaro Business Overview
- 12.14.3 Tesaro Revenue in Nausea And Vomiting Treatment Business (2021-2026)
- 12.14.4 Tesaro Nausea And Vomiting Treatment Product Portfolio
- 12.14.5 Tesaro Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst